The United States Department of Health has sanctioned the removal of the most stringent "black box" warnings from the packaging of three estradiol transdermal patches used for menopausal treatment.
American women face ongoing difficulties sourcing hormone replacement options like estrogen patches to address symptoms such as hot flashes, mood swings, and disrupted sleep amid a sharp rise in demand.
The Department of Health and Human Services did not immediately respond to requests seeking the specific brand names of the updated patches.
The decision follows earlier revisions in February, when the FDA authorized the removal of warnings regarding breast cancer, cardiovascular disease, and probable dementia from six menopausal hormone therapy items.
(Alamy/PA)
While the US Food and Drug Administration has been engaging with producers since September to bolster patch supplies, the agency has not officially designated them as being in a shortage.
"Estrogen patch market output has doubled over the past year,…